Target Database Clause Samples

The Target Database clause defines the specific database or set of databases to which the agreement or contract applies. It typically outlines the name, scope, and sometimes the location or version of the database, ensuring all parties are clear about the data assets involved. By precisely identifying the relevant database, this clause prevents ambiguity and potential disputes over which data is covered, thereby ensuring clarity and alignment between the parties.
Target Database. 5.1 The parties shall jointly set up and maintain a Target Database. The Target Database will hold the peptide sequence details identified as potential epitopes from the relevant Targets together with any other relevant and confidential details of any Target resulting from Joint Target Identification. The Target Database shall be maintained by the head of the Joint Target Identification group (“Database Controller”) who shall keep the contents of the Target Database up to date and shall maintain, modify and update the contents of the Target Database on behalf of both of Adaptimmune and Immunocore. Immunocore shall use all reasonable endeavours to procure that the Database Controller maintains any sequence information of any Target within the Target Database confidential on behalf of both parties despite such individual being an employee of Immunocore. The name of the head of the Joint Target Identification group as at the Effective Date is ▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ and Immunocore shall notify Adaptimmune of any change in identity of individual as soon as reasonably possible after becoming aware of any need for a change in individual, for example as a result of termination of employment. Immunocore shall ensure that there is always at least one Immunocore employee appointed as the Database Controller during the term of this Agreement. 5.2 Upon receipt of written notification from Adaptimmune or Immunocore that it wishes to initiate a T-cell Cloning directed to a specified Target, or that it has accepted a Target Nomination from a third party, the Database Controller shall provide the requesting party all contents of the Target Database specific to the Target or as relevant to any peptide sequence identified within such Target (including where such peptide sequence is present within more than one Target). Despite such release of sequence information Adaptimmune or Immunocore as relevant will use all reasonable endeavours to procure and maintain the ongoing confidentiality of the relevant sequence information. 5.3 Both parties may from time to time wish to discuss with Third Parties the practicability of developing products directed to a Target and this may include a requirement to confirm whether peptides from a Target proposed by a Third Party are already present within the sequences of Targets identified in the Target Database. In order to prevent contamination with Third Party supplied Target information each of Immunocore and Adaptimmune may request in writing tha...
View SourceView Similar (3)
Target Database. Until the earlier of (a) expiry of the Option Period or (b) Acceptance of three (3) Proposed Targets, Immunocore will provide Lilly access to an electronic data-room with information on all Targets evaluated by Immunocore and available for nomination as a Selected Target from time to time (“Target Database”). Lilly understands and accepts that the same Target Database will be made available to Lilly and all Third Party Partners (each an “Entity”). Immunocore and Lilly shall work together after the Effective Date to ensure that Lilly can access the Target Database and to agree the nomination and Acceptance of the third Selected Target and, subsequently to agree upon a written Research Plan for such Selected Target, with the first two (2) Selected Targets (i.e., the Initial Targets) being Accepted as of the Effective Date in accordance with Clauses 3.1.2 and 3.
View SourceView Similar (2)
Target Database. Following receipt of the Initial License Fee under Section 7.1 and continuing during the Option Period, Immunocore will provide GNE access to an electronic data-room with information on all Targets evaluated by Immunocore and available for nomination as an Exclusive Target from time to time (“Target Database”). GNE understands and accepts that the same Target Database will be made available to all relevant partners, licensees and potential licensees of Immunocore (each an “Entity”). Immunocore and GNE shall work together after the Effective Date to provide access to the Target Database, to agree the terms of relevant Research Plans and to provide the Materials under Section 5.1 promptly so as to enable the nomination and Acceptance of the first two (2) Exclusive Targets (and the agreed upon written Research Plan for such Exclusive Targets) within [***] after the Effective Date.
View SourceView Similar (2)

Related to Target Database

  • Database The LERG is available through Telcordia. ICONN is available through the Qwest web site.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Contract Database Metadata Elements Title: Sayville Union Free School District and Sayville Union Free School Custodial and Maintenance Employees Unit, United Public Service Employees Union (UPSEU), Local 424 (2011) Employer Name: Sayville Union Free School District Union: Sayville Union Free School Custodial and Maintenance Employees Unit, United Public Service Employees Union (UPSEU) Local: 424 Effective Date: 07/01/2011 Expiration Date: 06/30/2015 PERB ID Number: 6131 Unit Size: 55 Number of Pages: 24 For additional research information and assistance, please visit the Research page of the Catherwood website - ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇▇▇▇▇.▇▇▇/library/research/ For additional information on the ILR School - ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇▇▇▇▇.▇▇▇/ 55 People TABLE OF CONTENTS ARTICLE Page XXII ANNUAL LEAVE DAYS 14 XXV BREAKS 18 XXVI CIVIL SERVICE LAW ARTICLE SECTION 75 18 XXVIII DURATION 19 XIV EMERGENCY WORK 11 XXI FOUL WEATHER CLOTHING 14 XI GRIEVANCE PROCEDURE 9 XVI HIGHER JOB CLASSIFICATION 12 XVIII HOLIDAYS 13 XV HOLIDAY AND WEEKEND BUILDING CHECKS 12 V INSURANCE 4 X LAYOFF, DISPLACEMENT AND RECALL ORDER 8 VII MANAGEMENT RIGHTS 7 XXVII MISCELLANEOUS 19 XVII NOTICES OF PROMOTIONS 13 XIII OVERTIME 10 II PAYROLL DEDUCTIONS 1 III PERSONNEL FILES 2 XXIV PHYSICAL EXAMINATIONS 18 XXIII RETIREMENT 16 IX STRIKES AND LOCKOUTS 7 XIX VACATIONS 13 XX VISITATION 14 IV WAGES 3 VI WORKERS' COMPENSATION 6 XII WORKWEEK 10 VIII WRITTEN BOARD POLICY 8 APPENDIX A 20 4/20/2016 AGREEMENT made and entered into this day of November 2013 between the SAYVILLE UNION FREE SCHOOL DISTRICT (hereinafter referred to as the “District”) and United Public Service Employees Union, ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, N.Y. 11779 (hereinafter referred to as the “Union”).

  • Market Data Zero Hash may make certain information and research data, including historical market information available to you through the Platform or Zero Hash System, as applicable (“Market Data”). Market Data may be provided through third-party providers and may be updated at different time intervals, and accordingly, quotes, news, research data, market information and the various trade status reports, including intraday updates of balances and positions information and may differ due to the different Market Data and sources and their update intervals. Any such Market Data is provided as-is and for informational purposes only. Zero Hash makes no representation as to the accuracy or completeness of any Market Data. Further, Market Data may represent aggregated data from across multiple third-party trading venues and does not necessarily represent the prices of any asset as made available by Zero Hash or ZH Liquidity. Your reliance on any Market Data is at your sole discretion. The provision of Market Data relating to any asset shall not be considered Zero Hash’s, or its affiliates, endorsement of any such asset. You understand and agree that past performance of any asset is not indicative of future performance. You shall not decompile or redistribute any Market Data.

  • Background Data The Disclosing Party's Background Data, if any, will be identified in a separate technical document.